Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958035 · ClinicalTrials.gov registry record · Phase 4
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT00958035 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 89 participants.
The verdict
NCT00958035, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasing overall eyelash prominence in self-identified African American/ethnic black subjects exhibiting hypotrichosis of the eyelashes (inadequate or not enough eyelashes).
Interventions
- DRUG bimatoprost ophthalmic 0.03% solution
- DRUG vehicle sterile solution (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00958035
The ClinicalTrials.gov registry entry for NCT00958035 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bimatoprost ophthalmic 0.03% solution is the first listed.
NCT00958035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00958035 about?
NCT00958035 is a clinical study titled "Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis". This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasing overall eyelash prominence in self-identified African American/ethnic black subjects exhibiting hypotrichosis ...
What is the current status of trial NCT00958035?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2009-11. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00958035?
The interventions under investigation include: bimatoprost ophthalmic 0.03% solution (DRUG), vehicle sterile solution (placebo) (DRUG).
Who is sponsoring clinical trial NCT00958035?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.